PAVmed receives Nasdaq extension to Jan 2026 to meet $1 minimum bid price

PAVmed Inc.

Company failed to regain compliance by initial July 22, 2025 deadline after Jan 23 notice.
Nasdaq granted additional 180-day extension until January 19, 2026 for 10 consecutive $1 closing bids.
Stock continues trading under PAVM; PAVmed says it will consider all available options.
Failure to cure during extension could lead to delisting from Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.